What is Amneal Pharmaceuticals, Inc.'s debt issuance costs?

Amneal Pharmaceuticals, Inc. (AMRX) reported debt issuance costs of $1.98M in Q1 2026.

What does debt issuance costs mean?

Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.

Amneal Pharmaceuticals, Inc. AMRX Debt Issuance Costs

Debt Issuance Costs at other companies

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$722.5M+3.9%

Gross profit$320.1M+25.1%

Operating income$141.8M+41.3%

Net income$62.3M+411%

EPS (diluted)$0.19+375%

Balance sheet

See full

Cash & equivalents$197.7M+234%

Total debt$2.6B+17.7%

Total equity-$45.4M+65.5%

Total assets$3.5B+5.2%

Cash flow

See full

Operating cash flow-$26.7M-461%

CapEx$8.2M-37.9%

Free cash flow-$34.9M-507%

Valuation

See full

Market cap$5.17B+51.0%

Enterprise value$7.55B+33.4%

P/E42.4×—

P/S1.7×+0.5×

Profitability

See full

Gross margin38.7%+2.0pp

Operating margin14.3%+1.6pp

Net margin4%+3.6pp

FCF margin7.9%-1.0pp

Returns & leverage

See full

Return on equity-52.8%-12.7pp

Debt / equity127.9×+119×

Current ratio2.5×+1.1×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfFinancingCosts.

The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amneal Pharmaceuticals, Inc.'s debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s debt issuance costs?: Amneal Pharmaceuticals, Inc. (AMRX) reported debt issuance costs of $1.98M in Q1 2026.
What does debt issuance costs mean?: Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.